AZD0240 / AstraZeneca - LARVOL DELTA

Pre-clinical characterization of AZD0240, a CRISPR-engineered autologous TCR-T cell product targeting KRAS-G12D/HLA-A*11:01 that is multi-armored to increase epitope sensitivity (SITC 2025) - "Moreover, assessment of the in vitro and in vivo proliferative and cytotoxic capacity revealed that the AZD0240 armoring strategy profoundly increased both the clonal expansion and the anti-tumor efficacy of TCR-engineered T cells. Notably, the armored AZD0240 T cells were unable to respond to the KRAS G12 wild-type epitope, and no signs of increased TCR cross- or allo-reactivity, or malignant transformation were detected, derisking the clinical use of this armoring strategy.Conclusions Taken together, AZD0240 is a KRAS-G12D/HLA-A*11:01-targeted TCR-T cell therapy that employs a novel multi-armoring strategy and is currently in preparation for clinical testing, with encouraging signs of pre-clinical efficacy and safety."

Preclinical • Colorectal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

Pre-clinical characterization of AZD0240, a CRISPR-engineered autologous TCR-T cell product targeting KRAS-G12D/HLA-A*11:01 that is multi-armored to increase epitope sensitivity (CICON 2025) - "Notably, the armored AZD0240 T cells were unable to respond to the KRAS G12 wild-type epitope, and no signs of increased TCR cross- or allo-reactivity, or malignant transformation were detected, derisking the clinical use of this armoring strategy. Taken together, AZD0240 is a KRAS-G12D/HLA-A*11:01 targeted TCR-T cell therapy that employs a novel multi-armoring strategy and is currently in preparation for clinical testing, with encouraging signs of pre-clinical efficacy and safety."

Preclinical • Colorectal Cancer • Pancreatic Cancer • Solid Tumor • KRAS

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: AstraZeneca | Active, not recruiting ➔ Recruiting | Trial completion date: Aug 2042 ➔ Apr 2044

Enrollment open • Trial completion date • Colorectal Cancer • Endometrial Adenocarcinoma • Endometrial Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

Pre-clinical characterization of AZD0240, a CRISPR-engineered autologous TCR-T cell product targeting KRAS-G12D/HLA-A*11:01 that is multi-armored to increase epitope sensitivity (AACR 2025) - "Notably, the armored AZD0240 T cells were unable to respond to the KRAS G12 wild-type epitope, and no signs of increased TCR cross- or allo-reactivity, or malignant transformation were detected, derisking the clinical use of this armoring strategy. Taken together, AZD0240 is a KRAS-G12D/HLA-A*11:01 targeted TCR-T cell therapy that employs a novel multi-armoring strategy and is currently in preparation for clinical testing, with encouraging signs of pre-clinical efficacy and safety."

Preclinical • Colorectal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS